Health & Biotech France (H & B France, Paris, 2015) is a cell therapy company exploiting the potential of mesenchymal stem cells (MSCs) derived from the umbilical cord. The first advanced medicinal therapies developed target vascular pathologies and wound healing.
H & B France has developed a pro-angiogenic CSM production platform in accordance with GMP (Good Manufacturing Practices) standards, in partnership with the Advanced Therapies Medicinal Products Unit of the Army Blood Transfusion Centre (Percy Hospital, Clamart).
A first Phase I / IIa clinical trial will be launched in 2019, in partnership with the University Hospital of Reims, for allogeneic cell therapy in critical limb ischemia.
H & B France was founded by French and Chinese experts in stem cells, hematology and their clinical applications. The therapeutic developments of the company are selected on the basis of nearly twenty years of preclinical and clinical research on placental mesenchymal stem cells.